Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Revenues
Royalty and licensing revenue	$ 18,406,142	$ 5,097,595
Treatment investment revenue	39,854	4,800,000
Total revenue	18,445,996	9,897,595
Operating expenses
General and administrative	6,530,533	14,509,400
Research and development	3,171,599	2,808,757
Selling expenses	1,651,099	317,917
Total operating expenses	11,353,231	17,636,074
Income (loss) from operations	7,092,765	(7,738,479)
Other income (expense)
Interest income (expense), net	19,966	(11,890)
Income (loss) on foreign exchange	18,356	(63,887)
Total other income (expense)	38,322	(75,777)
Income (loss) before provision for income taxes	7,131,087	(7,814,256)
Provision for income taxes	550,474	0
Net income (loss)	$ 6,580,613	$ (7,814,256)
Income (loss) per share of common stock:
Basic income (loss) per share	$ 3.27	$ (4.09)
Diluted income (loss) per share	$ 2.94	$ (4.09)
Weighted average number of common stock outstanding:
Basic (in shares)	2,014,540	1,910,489
Diluted (in shares)	2,235,851	1,910,489